DemarestJ, UnderwoodM, St. ClairM, et al.: Dolutegravir-based regimens are active in integrase strand transfer inhibitor-naive patients with nucleoside reverse transcriptase inhibitor resistance. AIDS Res Hum Retroviruses, 2018; 34:343–346.
2.
CahnP, PozniakAL, MingroneH, et al.: : Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48 results from the randomized, double-bind, non-inferiority SAILING study. Lancet, 2013; 382:700–708.
3.
BlancoJL, MarcelinAG, KatlamaC, et al.: Dolutegravir resistance mutations: Lessons from monotherapy studies. Curr Opin Infect Dis, 2018; 31:237–245.
4.
WijtingI, LunguC, RijndersB, et al.: HIV-1 resistance dynamics in patients with virological failure to dolutegravir maintenance monotherapy. J Infect Dis, 2018; 218:688–697.
